Patient and Physician Preferences for Attributes Associated with Biologic Treatments for Hidradenitis Suppurativa

Bimekizumab in Patients with Moderate to Severe Hidradenitis Suppurativa: A Focus on Patient Quality of Life and Depth of Responses from BE HEARD I & II to Week 48

Bimekizumab Impact on Lesion Count by Anatomical Region in Moderate to Severe Hidradenitis Suppurativa: Results to Week 48 from BE HEARD I & II

Bimekizumab Impact on Dichotomous IHS4 Response Levels in Patients with Moderate to Severe Hidradenitis Suppurativa: Results up to Week 48 from BE HEARD I & II

Bimekizumab Efficacy by Disease Duration in Patients with Moderate to Severe Hidradenitis Suppurativa: Week 48 Results from BE HEARD I & II

IHS4 Outcomes with Bimekizumab in Patients with Moderate to Severe Hidradenitis Suppurativa: Pooled Results from the BE HEARD I & II Phase 3 Trials